This could have been a very good book. There are many things about our pink ribbon culture that are ripe for critique: the lack of access many women have to diagnostic and treatment services, the use of breast cancer as a marketing tool, the overselling of early diagnosis and the inexcusable tendency to ignore patients with metastatic cancer or even worse, blame them for the state of their disease. Instead, it descends into chemophobia, and when she discusses changes in disease mortality or incidence rates, she often cites conspiracy-mongering books written by non-scientists, because why cite the CDC, when you could just as easily cite a guy with a PhD in classics who once worked as a writer at a major cancer center? Perhaps the social sciences have vastly different standards, but citing books that peddle disproven conspiracy theories is generally frowned upon in the sciences.
The chemophobia leads her to exhort activists to condemn synthetic chemicals manufactured by corporations as possible causes of the rise in breast cancer and she repeatedly implies that this is one of the major drivers of recent rises in breast cancer rates. She points the reader to activist groups that are either uninterested in or silent on the strong links between alcohol and tobacco and breast cancer, but are very focused on chemicals that have caused tumors in animals at high doses or have shown to be endocrine disrupters in non-mammal systems.
Over and over, she implies that medical treatment of breast cancer is compromised because someone is making money and, well, capitalism. In science, we ask ourselves whether there is evidence to support a hypothesis. In this book, qui bono? appears to be the most important question. She repeatedly talks about conflicts of interest. On page 19, she sniffs out a conflict of interest when noting that AstraZeneca sponsored a mammography-promotion effort while also making chemicals. Later on she discusses “the pharmecutical industry’s fraudulent practices in pursuit of profits” pointing to Wyeth’s promotion of HRT. In her view, promoting it for prevention of heart disease while downplaying the breast cancer view amounts to fraud. I was a teenager in the 90’s when HRT really took off and even I knew that it raised your risk of breast cancer; the question was whether the purported cardiovascular benefits were worth it. It didn’t lower heart disease risk, but early studies came to that conclusion because the study designs were weak. Wyeth’s promotion of HRT’s cardiovascular benefits (they hired ghostwriters to create articles touting cardiovascular benefits) was clearly unethical, but unless medical sociology has an alternate definition of fraud (perhaps “stuff corporations do that I personally disagree with”), this doesn’t come close to fraud.
In general, the incidence of breast cancer has risen, while the mortality rate has dropped and the five year survival rate has risen. Some of this is likely due to overdiagnosis—the diagnosis of cancers that would have regressed or never caused symptoms. However, there have also been significant improvements in treatment – thanks to Herceptin and other drugs ER+ cancer’s prognosis has improved substantially as evidence, the age-adjusted death rate has dropped by about a third since 1975, while life expectancies for women have risen and the biggest cause of death, cardiovascular disease, has dropped. Sulik frequently insists that little progress has been made in the fight against breast cancer and flings out random and not particularly relevant statistics citing books by cranks. There are also insinuations that we’d have fewer cancers and better treatments if only some malevolent cancer industry – there isn’t any acknowledgement of just how complex cancers are and how difficult it is to find drugs that only or mostly kill the your mutated cells. One gets the impression that she’s decided to take the cancer people down and is just flinging everything she’s got at them in the hope that something will stick.
Occasionally, she trots out the point that women of color are less likely to get breast cancer, but far more likely to die of the disease. She doesn't really explore the reasons for this inexcusable situation: less access to diagnostic testing and empirically-validated treatment.
The best part of the book is a section of the book where she recounts interviews with breast cancer patients. It’s interesting to read what people with the disease think of it, but it’s bogged down by Sulik’s constant stressing of how women struggle because of the societal pressures to be carers or selfless or optimistic. This is an important problem, but she almost completely ignores the possibility that being diagnosed with a potentially deadly disease may play a role in their accounts. In the end, the book comes off as a very poorly argued polemic.